Stanford University
Showing 1-10 of 11 Results
-
Giselle (Ghazal) Salmasi, MD
Clinical Associate Professor, Medicine - Hematology
BioDr. Salmasi is a board-certified, fellowship-trained hematologist. She treats patients in the Hematology Program and the Hematologic Cancer Program at Stanford Health Care. Dr. Salmasi is the associate clinical chief for classical hematology. She is also a clinical associate professor in the Division of Hematology, Department of Medicine at Stanford University School of Medicine.
She treats a wide range of blood disorders and blood cancers. Her clinical/research interests include immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA). Dr. Salmasi understands that patients need social and emotional support along with medical care. She founded the earliest adolescent and young adult survivorship support groups in Santa Cruz, California, and Toronto, Canada. Dr. Salmasi is also dedicated to training future doctors in providing excellent hematologic care.
Dr. Salmasi was the medical co-investigator for a national phase 3 clinical trial of endovascular therapy for treating chronic venous thrombosis.
Her research has appeared in the New England Journal of Medicine, Leukemia & Lymphoma journal and the Transfusion and Apheresis Science journal. Dr. Salmasi’s publications include articles and a chapter about lymphoma. She has also reviewed articles for the Biology of Blood and Marrow Transplantation journal and the Journal of Clinical Oncology.
Dr. Salmasi is a member of the American Society of Hematology. -
Alexander Isaac Salter
Affiliate, Department Funds
Fellow in Medicine - Med/HematologyBioI am a clinical fellow in medical oncology at Stanford University whose long-term goal is to become a translational physician-scientist who develops curative cellular immunotherapies for solid tumors. As a graduate student, I conducted the first comprehensive signaling analyses of therapeutically engineered T cells, demonstrating that signal strength, rather than quality, is a key determinant of T cell function and fate. These findings helped inform the design of next-generation cellular immunotherapies, some of which are now in clinical trials. I also co-led a collaboration with Dr. David Baker’s laboratory at the University of Washington to engineer synthetic protein “logic gates” enabling combinatorial antigen recognition with high precision, offering a potential path to more safely target solid tumors. My doctoral research resulted in 16 publications, including four prominent first-, co-first-, or second-author papers in high-impact journals, several reviews and textbook chapters, and recognition on the Forbes 30 Under 30 List.
At Stanford, I focus on translating cellular therapies for thoracic and genitourinary malignancies. Under the mentorship of Drs. Crystal Mackall and Allison Betof Warner, I am developing CAR T cells for lung cancer in non- and never-smokers and serve as a sub-investigator on an upcoming first-in-human phase 1 trial of drug-regulatable CAR T cells for adults with advanced solid tumors. -
William Shomali
Clinical Assistant Professor, Medicine - Hematology
BioDr. Shomali is a clinical assistant professor of Hematology at Stanford University School of Medicine. He is board certified in hematology & medical oncology.
Dr. Shomali specializes in the treatment of blood cancers such as myeloproliferative neoplasms and myelodysplastic syndromes. He aims to provide compassionate, personalized, and evidence-based care to each patient.
Dr. Shomali received his medical degree from the University of Jordan, followed by a postdoctoral fellowship at MD Anderson Cancer Center where he studied infections in cancer patients and the role of biomarkers in defining tumor fever. He completed his residency training in Internal Medicine at the Cleveland Clinic Foundation where he served as a Chief Medical Resident. He then joined Stanford University for his combined Hematology & Oncology fellowship training.
Dr. Shomali’s research interests include the study of novel agents in myeloproliferative neoplasms and myelodysplastic syndromes. He developed investigator-initiated clinical trials for patients with eosinophilic neoplasms and advanced myelofibrosis. In addition, he co-authored several papers and book chapters discussing the care of patients with cancer. His work has been presented in national meetings and published in peer reviewed journals including Blood, American Journal of Hematology, British Journal of Hematology, Leukemia & Lymphoma, and Cancer.
Among his honors, Dr. Shomali received the Cleveland Clinic Excellence in Teaching Award and was named to the Alpha Omega Alpha Medical Honor Society. He has received a Young Investigator Award from the Conquer Cancer Foundation, an NIH Institutional National Research Service Award, and a Stanford Cancer Institute Fellowship Award.
Dr. Shomali is a member of the American Society of Hematology and the American Society of Clinical Oncology. -
Adam Sperling, MD, PhD
Affiliate, Medicine - Med/Hematology
BioDr. Sperling received his medical degree and PhD in Biological Chemistry from the University of California, Los Angeles in 2011. He completed his residency in internal medicine at the Brigham and Women's Hospital and his fellowship in Hematology and Oncology at the Dana-Farber Cancer Institute. He received board certification from the American Board of Internal Medicine in 2014, in Medical Oncology in 2017 and in Hematology in 2018. He was a member of the staff at the Dana-Farber Cancer Institute and the Brigham and Women's Hospital in Boston from 2018-2026, where he was an Assistant Professor of Medicine at Harvard Medical School. He joined the faculty at Stanford University in 2026, where he is a hematologist and basic and translational researcher in hematologic malignancies. He cares for patients with multiple myeloma and related blood cancers and his research focuses on understanding the mechanisms of disease evolution from pre-malignant conditions and the development of drug resistance in multiple myeloma and other hematologic malignancies.
